Verge Genomics

San Francisco, United States Founded: 2015 • Age: 11 yrs
Neurodegenerative disease drugs are developed using computational genomics.
Request Access

About Verge Genomics

Verge Genomics is a company based in San Francisco (United States) founded in 2015 by Jason Chen.. Verge Genomics has raised $134.5 million across 4 funding rounds from investors including Lilly, WuXi AppTec and BlackRock. The company has 38 employees as of December 31, 2024. Verge Genomics offers products and services including CONVERGE Platform and VRG50635. Verge Genomics operates in a competitive market with competitors including Biogen, Insitro, BridgeBio, ATAI and Denali Therapeutics, among others.

  • Headquarter San Francisco, United States
  • Employees 38 as on 31 Dec, 2024
  • Founders Jason Chen
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Verge Analytics, Inc.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $134.5 M (USD)

    in 4 rounds

  • Latest Funding Round
    $98 M (USD), Series B

    Dec 16, 2021

  • Investors
    Lilly

    & 21 more

  • Employee Count
    38

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Verge Genomics

Verge Genomics offers a comprehensive portfolio of products and services, including CONVERGE Platform and VRG50635. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

AI system for mapping disease causes and developing drug candidates.

Small molecule inhibitor targeting ALS and other neurological conditions.

People of Verge Genomics
Headcount 10-50
Employee Profiles 12
Board Members and Advisors 11
Employee Profiles
People
Ines Hoffman
Director & Head, Clinical Operations
People
Effie Bruzik
VP, Operations
People
Erin Holton
Executive Assistant
People
Alice Zhang
CEO & Co-Founder

Unlock access to complete

Board Members and Advisors
people
Emily Melton
Director
people
Saira Ramasastry
Advisory Board Member
people
Mario Saltarelli
Advisory Board Member
people
Andrew Allen
Director

Unlock access to complete

Funding Insights of Verge Genomics

Verge Genomics has successfully raised a total of $134.5M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $98 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 4
  • Last Round Series B — $98.0M
  • First Round

    (21 Jul 2015)

  • Investors Count 22
Date Amount Transaction Name Valuation Lead Investors Investors
Dec, 2021 Amount Series B - Verge Genomics Valuation BlackRock
Jul, 2018 Amount Series A - Verge Genomics Valuation DFJ , WuXi AppTec
Nov, 2015 Amount Seed - Verge Genomics Valuation IA Ventures , Two Sigma Ventures
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Verge Genomics

Verge Genomics has secured backing from 22 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Lilly, WuXi AppTec and BlackRock. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Angel
Investor Description Founded Year Domain Location
Corporate-backed venture capital is focused on the life science sector.
Founded Year Domain Location
A venture capital fund focused on biotech for neurodegeneration.
Founded Year Domain Location
Venture capital firm focused on multiple sectors
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Verge Genomics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Verge Genomics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Verge Genomics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Verge Genomics

Verge Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Insitro, BridgeBio, ATAI and Denali Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Therapies for neurodegenerative and immunology disorders are developed.
domain founded_year HQ Location
An AI-enabled platform is developed for infectious disease treatment.
domain founded_year HQ Location
Therapeutics for genetic diseases are developed through targeted interventions.
domain founded_year HQ Location
A biopharmaceutical company accelerating innovative mental health treatments.
domain founded_year HQ Location
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
domain founded_year HQ Location
Cloud-based genome informatics and data management are provided.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Verge Genomics

When was Verge Genomics founded?

Verge Genomics was founded in 2015.

Where is Verge Genomics located?

Verge Genomics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.

Is Verge Genomics a funded company?

Verge Genomics is a funded company, having raised a total of $134.5M across 4 funding rounds to date. The company's 1st funding round was a Seed of $4M, raised on Jul 21, 2015.

How many employees does Verge Genomics have?

As of Dec 31, 2024, the latest employee count at Verge Genomics is 38.

What does Verge Genomics do?

Verge Genomics was founded in 2015 in San Francisco, United States, within the biotechnology sector. Therapeutics for neurodegenerative diseases are developed through computational genomics, leveraging proprietary datasets from human samples. Disease-causing genes are mapped, and drugs are identified to target multiple genes concurrently. Conditions addressed include amyotrophic lateral sclerosis, Parkinsons disease, and frontotemporal dementia. Network algorithms are applied to genomic data to support this process.

Who are the top competitors of Verge Genomics?

Verge Genomics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.

What products or services does Verge Genomics offer?

Verge Genomics offers CONVERGE Platform and VRG50635.

Who are Verge Genomics's investors?

Verge Genomics has 22 investors. Key investors include Lilly, WuXi AppTec, BlackRock, Merck Global Health Innovation Fund, and Vulcan Aerospace.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available